Modiodal (Modafinil)

Modafinil primarily inhibits the reuptake of dopamine, increasing its concentration in the brain. It also activates hypothalamic orexin neurons, which play a key role in regulating arousal. Together, these actions enhance alertness without the strong sympathomimetic effects seen with traditional stimulants.

The appropriate dose of Modiodal is determined by a qualified prescriber based on the individual’s medical condition, response to therapy, and overall health status. Healthcare professionals will tailor the regimen to achieve optimal wakefulness while minimizing potential adverse effects.

Safety data for modafinil in pregnancy and lactation are limited, and the product’s pregnancy category is not established. Clinicians should weigh potential benefits against possible risks and consider alternative therapies when treating pregnant or nursing individuals.

To request Modiodal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Modiodal (modafinil) differs from traditional stimulants such as methylphenidate by having a lower propensity for cardiovascular stimulation and a longer half‑life, which provides sustained wakefulness with once‑daily dosing. Its mechanism focuses on dopamine reuptake inhibition and orexin activation rather than direct adrenergic stimulation.

Modiodal should be stored at ambient temperature, preferably below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight to maintain stability throughout its shelf life.

Modiodal is taken orally, typically with a glass of water. It can be taken with or without food, but patients should follow the prescribing clinician’s instructions regarding timing relative to meals to ensure consistent absorption.

Serious risks include severe skin reactions such as Stevens‑Johnson syndrome, psychiatric events like hallucinations or mania, and cardiovascular complications such as hypertension or arrhythmia. Patients should seek immediate medical attention if they experience rash, mood changes, chest pain, or difficulty breathing.

Modiodal is contraindicated in individuals with known hypersensitivity to modafinil or any of its excipients. Caution is advised for patients with uncontrolled hypertension, significant cardiac disease, or a history of severe psychiatric disorders. Clinicians should evaluate each patient’s medical history before initiating therapy.